Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In episode 2 of an ongoing series of sharing sessions between a physician and patient, Robert Gish, MD, FAASLD, and patient advocate, Alan Wang, discuss stigma as a barrier to optimal HBV care and treatment. The conversation focuses on how stigma affected Alan’s engagement with his care and strategies to overcome stigma as a barrier to HBV care.
Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
University of Nevada Reno School of Medicine
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Hepatitis B Foundation
This program has been made available online.
Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)
Clinical Care Options (CCO) commentary from Dr Carla Coffin on risks vs benefits of treating patients in the indeterminate category for HBV treatment
Clinical Care Options (CCO) expert audio: Dr Pietro Lampertico discusses the importance of continued HBV monitoring in patients without indications for immediate treatment
Dr Norah Terrault: missed opportunities for hepatitis delta virus (HDV) testing and how to overcome them, from Clinical Care Options (CCO)